Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now soon they may be unavailable to most.

Eli Lily's GLP-1 competitor Mounjaro/Zepbound doesn't make the list, but that is because it has not been on the market long enough to be up for consideration. The list of 15 drugs (up from 10 in ...

Lily’s purchase was agreed in July, and will set the company back $1.93 billion on completion to takeover Versanis Bio. The biotech’s main asset is bimagrumab, a monoclonal antibody that could ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

A new trend emerged which reportedly saw stars microdosing or taking tiny amounts of Ozempic and other GLP-1 weight-loss jabs like Mounjaro, Wegovy or Zepbound to effortlessly attain that Awards ...

Eli Lilly: The U.S. drugmaker’s weight-loss drug Zepbound became the direct rival for Novo Nordisk’s Wegovy, when it was approved by FDA in 2023. The healthcare giant, in July 2023 ...